-+ 0.00%
-+ 0.00%
-+ 0.00%

Benchmark Maintains Speculative Buy on Harvard Bioscience, Raises Price Target to $7.5

Benzinga·08/12/2026 12:58:22
Listen to the news
Benchmark analyst Bruce D. Jackson maintains Harvard Bioscience (NASDAQ:HBIO) with a Speculative Buy and raises the price target from $6 to $7.5.